Horizon Pharma PLC (HZNP)

16.47
0.33 2.00
NASDAQ : Health Care
Prev Close 16.80
Open 16.74
Day Low/High 16.27 / 16.94
52 Wk Low/High 12.86 / 38.59
Volume 2.56M
Avg Volume 4.10M
Exchange NASDAQ
Shares Outstanding 161.26M
Market Cap 2.72B
EPS 0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Notable Friday Option Activity: HZNP, GPRO, TRUE

Notable Friday Option Activity: HZNP, GPRO, TRUE

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Horizon Pharma plc , where a total volume of 44,746 contracts has been traded thus far today, a contract volume which is representative of approximately 4.5 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 89.5% of HZNP's average daily trading volume over the past month, of 5.0 million shares.

Horizon Pharma Tanks on Failed Late-Stage Study

Horizon Pharma Tanks on Failed Late-Stage Study

Horizon's nueromuscular disorder treatment trials failed.

Horizon Fails Late-Stage Freidreich's Ataxia Trial

Horizon Fails Late-Stage Freidreich's Ataxia Trial

Shares spiraled downward in early trading, but Mizuho's Irina Koffler expects the stock will plateau by the end of the day.

'Mad Money Lightning Round: Buy, Buy, Buy Western Digital

'Mad Money Lightning Round: Buy, Buy, Buy Western Digital

Cramer says FedEx will have a merry holiday season but he's avoiding Seaspan.

Jim Cramer's 'Mad Money' Recap: The Trump Rally Is Showing Cracks

Jim Cramer's 'Mad Money' Recap: The Trump Rally Is Showing Cracks

Stocks once considered free of risks aren't any longer, Cramer warns.

Notable Monday Option Activity: HZNP, STAR, ELS

Notable Monday Option Activity: HZNP, STAR, ELS

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Horizon Pharma plc , where a total volume of 15,150 contracts has been traded thus far today, a contract volume which is representative of approximately 1.5 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 42.3% of HZNP's average daily trading volume over the past month, of 3.6 million shares.

Mad Money Lightning Round: Cramer Doesn't Want Health-Care Headaches

Mad Money Lightning Round: Cramer Doesn't Want Health-Care Headaches

Horizon Pharma is a 'giant headache,' says Jim Cramer; Abbot Labs is OK long term.

Jim Cramer's Mad Money: Keep One Eye on Earnings, the Other on Politics Next Week

Jim Cramer's Mad Money: Keep One Eye on Earnings, the Other on Politics Next Week

Holiday-shortened week holds a feast of earnings reports, says Jim Cramer.

Jim Cramer's 'Mad Money' Recap: Get Your Shopping List Ready for Next Week

Jim Cramer's 'Mad Money' Recap: Get Your Shopping List Ready for Next Week

No matter who wins the election, Jim Cramer says, there are ways to make money.

Depomed Reports Dip in Earnings, Reduces Revenue Guidance

Depomed Reports Dip in Earnings, Reduces Revenue Guidance

Despite a win in court over its patents and a deal with activist investors, Depomed shares dropped after it gave a reduced guidance for 2016 revenues.

How Do the Charts Look for Jim Cramer's Weekly Shopping List?

How Do the Charts Look for Jim Cramer's Weekly Shopping List?

No matter who wins the election, there are ways to make money.

Noteworthy Thursday Option Activity: HZNP, AIRM, CVT

Noteworthy Thursday Option Activity: HZNP, AIRM, CVT

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Horizon Pharma plc , where a total volume of 22,226 contracts has been traded thus far today, a contract volume which is representative of approximately 2.2 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 80.8% of HZNP's average daily trading volume over the past month, of 2.8 million shares.

Drug Win for Depomed Could Be Hurdle for Starboard

Drug Win for Depomed Could Be Hurdle for Starboard

Increased chance for company's sale presents activist campaign with a steeper climb.